YPSN Share Price Performance
CHF 0
-425.00 (-100.00%)
Price CHF 0
Fair ValueCHF 387.83
Share Pricen/a
Narrative Update • Jul 06
Ypsomed Holding AG Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
YPSN Community Narratives
AN
Fair Value
·Fair Value CHF 387.83 2.6% undervalued intrinsic discount
Analysts Revise Ypsomed Target Downward Amid Mixed Views on Growth and Margins
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value CHF 301.03 25.4% overvalued intrinsic discount
Overcapacity And Regulatory Challenges Will Limit Future Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value CHF 440 14.2% undervalued intrinsic discount
Connected Self-Injection Devices Will Redefine Chronic Care Globally
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Connected Self-Injection Devices Will Redefine Chronic Care Globally
Ypsomed is shifting into a focused maker of at-home injection devices, aiming to ride the move toward home-based chronic care and drug companies outsourcing these devices to trusted partners. The upside is stronger, more predictable demand through big pharma relationships, but heavy spending, pricing pressure, and potential new treatment methods could strain profits.Read more
AN
CHF 440
14.2% undervalued intrinsic discount
Fair Value
Revenue
9.06% p.a.
Profit Margin
27.42%
Future PE
21.16x
Price in 2029
CHF 467.8
Analysts Revise Ypsomed Target Downward Amid Mixed Views on Growth and Margins
Ypsomed is reshaping itself into a behind-the-scenes partner for drug companies, betting that a tighter focus and new factories closer to key markets can make the business more efficient. The upside comes from a busy pipeline of new drug delivery projects, but big expansion plans and reliance on a few markets could make results choppier than they look.Read more
AN
CHF 387.83
2.6% undervalued intrinsic discount
Fair Value
Revenue
7.13% p.a.
Profit Margin
26.18%
Future PE
20.62x
Price in 2029
CHF 412.65
Overcapacity And Regulatory Challenges Will Limit Future Potential
Ypsomed is spending heavily to expand its manufacturing, but that bet could backfire if demand for injectable drug devices cools or big partners change course. At the same time, tougher healthcare rules and fast-moving digital competitors could squeeze pricing and make today’s products feel dated.Read more
AN
CHF 301.03
25.4% overvalued intrinsic discount
Fair Value
Revenue
4.88% p.a.
Profit Margin
25.47%
Future PE
17.53x
Price in 2029
CHF 320.24
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
YPSN: Pipeline Execution And Dividend Payout Will Drive Future Upside
Fair Value: CHF 440 14.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
YPSN: Mixed Research Views And Dividend Outlook Will Shape Future Returns
Fair Value: CHF 387.83 2.6% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
YPSN: Cautious Outlook As Medium Term Sales Face New Headwinds
Fair Value: CHF 301.03 25.4% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ypsomed Holding AG Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Nov 11, 2026
- 16.88
- 43.04%
- 30.36%
- 34.9%
About YPSN
- Founded
- 1984
- Employees
- 2025
- CEO
- WebsiteView website
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally. The company offers various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other related services. It offers contract manufacturing of infusion sets and reservoirs. The company markets its products to hospitals, doctors, pharmacies and patients via subsidiaries and distributors. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Recent YPSN News & Updates
Narrative Update • Jun 22
